A laboratory-made four-amino-acid chain copying a substance from the small brain structure that sets the sleep-wake cycle. In cultured human cells it lengthens the protective caps on chromosomes — restarting a step most cancers take. Animal work shows modest survival gains. Human evidence comes only from the Russian institute that patented it. Unapproved everywhere, sold unverified, barred from competitive sport. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Nocturnal salivary melatonin | Peak > 10 pg/mL between 02:00 and 04:00 | Establishes whether the circadian deficit the compound targets is present |
| Leukocyte telomere length | Above the 50th percentile for age | The primary mechanistic endpoint claimed for this compound |
| hs-CRP | < 0.5 mg/L | General inflammatory load, and the marker most likely to move if the reported anti-inflammatory effect is real |
| Fasting glucose | 75-85 mg/dL (4.2-4.7 mmol/L) | Detects both the reported metabolic benefit and the additive hypoglycemia risk |
| Fasting insulin and HOMA-IR | Insulin 2-5 µIU/mL; HOMA-IR < 1.0 | More sensitive than glucose to the pineal-pancreatic effect reported in aged primates |
| HbA1c | 4.8-5.3% | Confirms whether any glucose change persists beyond the course |
| Complete blood count with differential | Within reference range, with stable lymphocyte and neutrophil counts | Screens for the immune modulation the compound is reported to produce, and for hematological malignancy |
| Comprehensive metabolic panel | Liver enzymes in the lower half of range; eGFR > 90 mL/min/1.73 m² | Baseline organ function, and detection of any unexpected hepatic or renal signal |
| IGF-1 | Age-adjusted 50th-75th percentile | Growth-signaling tone, relevant to the proliferative side of the cancer question |
| PSA (men over 45) | < 1.0 ng/mL, with velocity < 0.35 ng/mL per year | Cancer surveillance, given the theoretical telomerase-related proliferative risk |
| Morning cortisol | 10-15 µg/dL at 08:00 | Confirms the stress axis is intact, since a disrupted cortisol rhythm works directly against the circadian mechanism |
Cadence: Full panel drawn and reviewed before the first injection, with age- and sex-appropriate cancer screening completed. Metabolic subset (fasting glucose, fasting insulin, HbA1c) plus hs-CRP at the end of the first course, approximately 3 weeks after starting. Full panel at 6 months, then every 6-12 months for as long as use continues. Leukocyte telomere length no more often than every 12-24 months. On insulin or a sulfonylurea, self-monitored glucose at least twice daily through the first week of every course.